Library / Laws / 119th Congress / Senate Bills / S. 1096
S. 1096
To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in Senate | 2025-03-24 | 21.6K | ⠃⠗⠋ |
| Reported in Senate | 2025-04-10 | 42.8K | ⠃⠗⠋ |